American Century Companies Inc. Has $1.14 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

American Century Companies Inc. increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 14.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 7,184 shares of the biotechnology company’s stock after purchasing an additional 889 shares during the quarter. American Century Companies Inc.’s holdings in Sarepta Therapeutics were worth $1,135,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Capital International Investors lifted its holdings in shares of Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after buying an additional 2,917,797 shares during the last quarter. Farallon Capital Management LLC raised its stake in Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after acquiring an additional 319,444 shares in the last quarter. Principal Financial Group Inc. raised its stake in Sarepta Therapeutics by 693.7% during the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock worth $57,356,000 after acquiring an additional 317,277 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after buying an additional 243,180 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SRPT. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, September 19th. Morgan Stanley restated an “overweight” rating and set a $165.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. Leerink Partners raised their target price on Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, June 24th. Piper Sandler reduced their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, BMO Capital Markets lifted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Three analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $187.39.

Sarepta Therapeutics Stock Up 0.3 %

NASDAQ:SRPT opened at $124.89 on Tuesday. The firm has a market capitalization of $11.81 billion, a price-to-earnings ratio of 1,135.36 and a beta of 0.81. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $173.25. The stock’s 50 day moving average price is $134.56 and its two-hundred day moving average price is $132.86. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.27) EPS. Equities research analysts expect that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael Andrew Chambers bought 37,038 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. The disclosure for this purchase can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.